A 48-year-old woman with CKD stage 5 (eGFR 12 mL/min/1.73 m²) on hemodialysis presents with hemoglobin 7.8 g/dL, serum iron studies showing ferritin 450 ng/mL and transferrin saturation 22%, and EPO resistance (on 300 IU/kg/week). What is the drug of choice to improve anemia response in this patient?

Explanation

## Management of EPO-Resistant Anemia in CKD **Key Point:** Iron deficiency is the most common cause of EPO resistance in CKD. Intravenous iron supplementation is the first step in managing EPO-resistant anemia, even when ferritin appears adequate. ### Diagnosis of Functional Iron Deficiency This patient has: - Hemoglobin 7.8 g/dL (severe anemia) - Ferritin 450 ng/mL (appears adequate) - Transferrin saturation 22% (LOW—normal >20% but functional iron deficiency exists when TSAT <20%) - EPO resistance despite adequate dosing **Clinical Pearl:** Ferritin is an acute-phase reactant and may be falsely elevated in inflammation. **Transferrin saturation <20%** is the key indicator of functional iron deficiency, meaning iron is not available to erythroid precursors despite adequate iron stores. ### Why IV Iron Sucrose? 1. **Addresses functional iron deficiency**: IV iron bypasses GI absorption and rapidly replenishes iron available to erythropoiesis. 2. **Improves EPO responsiveness**: Once iron is repleted, EPO efficacy improves dramatically. 3. **Standard in dialysis**: IV iron is preferred in CKD stage 5 on dialysis because: - Oral iron is poorly absorbed in uremia - IV iron can be given during dialysis sessions - Iron sucrose has a favorable safety profile (less labile iron than iron dextran) ### Comparison of Iron Formulations | Formulation | Route | Dose/Session | Advantages | Disadvantages | |-------------|-------|--------------|------------|---------------| | **Iron sucrose** | IV | 100–200 mg | Safer, less anaphylaxis, preferred | More expensive | | **Iron dextran** | IV/IM | 50–100 mg | Cheaper | Higher anaphylaxis risk | | **Ferrous sulfate** | Oral | 325 mg daily | Cheap | Poor absorption in CKD | ### Why Not the Other Options? - **Increase EPO dose**: Already at 300 IU/kg/week; further escalation without iron repletion will not improve hemoglobin and increases cardiovascular risk. - **Folic acid**: Useful only if folate deficiency is documented; not the primary driver of EPO resistance here. - **Darbepoetin alfa**: A longer-acting ESA, but it does not address the underlying iron deficiency; switching agents without iron repletion will fail. **High-Yield:** In EPO-resistant anemia with low TSAT, always give IV iron first. Only escalate ESA dose or switch agents after iron is repleted and EPO responsiveness is reassessed. **Mnemonic: IRON FIRST** — In EPO-resistant anemia, **I**V iron, **R**ule out **O**ther causes (infection, bleeding, hemolysis), **N**ormalize iron stores. **F**irst step, **I**ntravenous route, **R**apid response, **S**ucrose formulation, **T**ransferrin saturation target >20%.